Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold

Analysts see potential in Iovance's pipeline and commercial ramp, but remain cautious on short-term outlook.

Feb. 28, 2026 at 7:42am

Got story updates? Submit your updates here. ›

Wall Street Zen, an equity research firm, has upgraded its rating on Iovance Biotherapeutics (NASDAQ:IOVA) from "sell" to "hold". The upgrade comes after Iovance reported better-than-expected Q4 and full-year 2025 financial results, driven by strong sales of its lead product Amtagvi. Analysts also cited Iovance's pipeline progress and plans for a registrational sarcoma study as reasons for the improved outlook, though they remain cautious on the stock's short-term performance due to high short interest.

Why it matters

Iovance is a clinical-stage biotech company focused on developing tumor-infiltrating lymphocyte (TIL) immunotherapies for solid tumors. The upgrade from Wall Street Zen signals that analysts see potential in Iovance's commercial ramp and pipeline, though concerns remain around execution risk and stock volatility driven by high short interest.

The details

In its research note, Wall Street Zen cited Iovance's Q4 2025 revenue of ~$87 million, representing 30% growth quarter-over-quarter, and full-year revenue of ~$264 million, up 61% year-over-year. The analysts also pointed to Iovance's plans for a registrational sarcoma study and positive 50% overall response rate (ORR) data as contributing to the improved outlook. However, the firm maintained a "hold" rating due to Iovance's high short interest, which jumped 24.8% to 131 million shares (36.9% of float) with a 14.6 day cover ratio, leaving the stock vulnerable to volatility and potential short squeezes.

  • Iovance reported Q4 2025 results on February 24, 2026.
  • Iovance announced plans for a registrational sarcoma study and positive 50% ORR data in recent weeks.

The players

Wall Street Zen

An equity research firm that covers Iovance Biotherapeutics and has upgraded the stock from "sell" to "hold".

Iovance Biotherapeutics

A clinical-stage biotechnology company specializing in the development and commercialization of tumor-infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.